Page last updated: 2024-12-08

ingenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID442042
CHEMBL ID2165402
CHEBI ID5922
SCHEMBL ID317087
SCHEMBL ID17691258
MeSH IDM0051704

Synonyms (29)

Synonym
BCBCMAP01_000158
SMP1_000044
ingenol ,
C09112
30220-46-3
S9101
1aalpha,2alpha,5beta,5abeta,6beta,beta,9 alpha, 10,10aalpha-octahydro-5,5a,6-trihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-1h-2,8aalpha-methano cyclopenta(a)cyclopropa(e)cyclodecen-11-one
ic77uzi9g8 ,
unii-ic77uzi9g8
CHEMBL2165402
CHEBI:5922 ,
(1ar,2s,5r,5ar,6s,8as,9r,10ar)-5,5a,6-trihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-1a,2,5,5a,6,9,10,10a-octahydro-1h-2,8a-methanocyclopenta[a]cyclopropa[e][10]annulen-11-one
SCHEMBL317087
ingenol, (+)-
ingenol [mi]
ingenol [who-dd]
(+)-ingenol
1h-2,8a-methanocyclopenta(a)cyclopropa(e)cyclodecen-11-one, 1a,2,5,5a,6,9,10,10a-octahydro-5,5a,6-trihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-, (1ar,2s,5r,5ar,6s,8as,9r,10ar)-
1h-2,8a-methanocyclopenta(a)cyclopropa(e)cyclodecen-11-one, 1a,2,5,5a,6,9,10,10a-octahydro-5,5a,6-trihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-, (1ar-(1a.alpha.,2.beta.,5.beta.,5a.beta.,6.beta.,8a.alpha.,9.alpha.,10a.alpha.))-
SCHEMBL17691258
J-017834
(-)-ingenol
AS-75318
(1s,4s,5r,6r,9s,10r,12r,14r)-4,5,6-trihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyltetracyclo[7.5.1.0(1),?.0(1)?,(1)(2)]pentadeca-2,7-dien-15-one
VEBVPUXQAPLADL-POYOOMFHSA-N
Q27106930
CCG-268016
(1s,4s,5r,6r,9s,10r,12r,14r)-4,5,6-trihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyltetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dien-15-one
I1112

Research Excerpts

Overview

Ingenol is a diterpenoid with unique architecture and has derivatives possessing important anticancer activity. Picato is a first-in-class drug for the treatment of the precancerous skin condition actinic keratosis.

ExcerptReferenceRelevance
"Ingenol is a diterpenoid with unique architecture and has derivatives possessing important anticancer activity, including the recently Food and Drug Administration-approved Picato, a first-in-class drug for the treatment of the precancerous skin condition actinic keratosis. "( 14-step synthesis of (+)-ingenol from (+)-3-carene.
Baran, PS; Felding, J; Jørgensen, L; Kuttruff, CA; McKerrall, SJ; Ungeheuer, F, 2013
)
2.14

Actions

ExcerptReferenceRelevance
"Ingenol-B does not inhibit HIV-specific CD8+ T cell responses in vitro. "( The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells.
Blankson, JN; Gama, L; Goldsborough, K; Kwaa, AK; Pianowski, LF; Walker-Sperling, VE, 2017
)
2.26

Toxicity

ExcerptReferenceRelevance
" Primary outcomes included maximum composite local skin response (LSR) score and adverse events (AEs)."( A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis.
McEniery, E; Primiero, C; Prow, TW; Selmer, J; Sinnya, S; Soyer, HP; Tan, JM; Østerdal, ML, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction."( Characterization of the interaction of ingenol 3-angelate with protein kinase C.
Blumberg, PM; Garfield, SH; Kedei, N; Lundberg, DJ; Toth, A; Welburn, P, 2004
)
0.59
"LEO 43204 had a similar safety profile to ingenol mebutate and a dose-response relationship for LSRs was demonstrated."( A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis.
McEniery, E; Primiero, C; Prow, TW; Selmer, J; Sinnya, S; Soyer, HP; Tan, JM; Østerdal, ML, 2016
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
tetracyclic diterpenoidA diterpenoid with a tetracyclic skeleton.
cyclic terpene ketoneAn alicyclic ketone in which the carbocyclic ring structure forms part of a terpene skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1406279Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells2018European journal of medicinal chemistry, Aug-05, Volume: 156Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui.
AID772945Chemical stability of the compound in aqueous buffer assessed as drug recovery after 16 hrs at pH 7.4 by HPLC analysis2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
AID772942Induction of TNFalpha release in human primary epidermal keratinocytes after 6 hrs2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1543133Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay2019Journal of natural products, 06-28, Volume: 82, Issue:6
Potent Anti-HIV Ingenane Diterpenoids from Euphorbia ebracteolata.
AID772938Induction of necrosis in human HeLa cells after 30 mins by resazurin assay2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
AID1406278Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui.
AID1286239Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay2016Journal of natural products, Jan-22, Volume: 79, Issue:1
Diterpenoids from the Roots of Euphorbia fischeriana with Inhibitory Effects on Nitric Oxide Production.
AID1305722Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Jatrophane and ingenane-type diterpenoids from Euphorbia kansui inhibit the LPS-induced NO production in RAW 264.7 cells.
AID1286240Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at nitric oxide IC50 level by MTT assay2016Journal of natural products, Jan-22, Volume: 79, Issue:1
Diterpenoids from the Roots of Euphorbia fischeriana with Inhibitory Effects on Nitric Oxide Production.
AID1231849Selectivity index, CC50 for african green monkey Vero cells to EC50 for HIV1 3B2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID1543134Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV NL4-3 infected in human MT4 cells2019Journal of natural products, 06-28, Volume: 82, Issue:6
Potent Anti-HIV Ingenane Diterpenoids from Euphorbia ebracteolata.
AID772944Induction of oxidative burst in polymorphonuclear leukocytes (unknown origin) isolated from buffy coat after 40 mins by fluorescence assay2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
AID1231847Selectivity index, CC50 for african green monkey Vero cells to EC50 for chikungunya virus Indian ocean strain 8992015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID1231846Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID1231848Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID772939Induction of IL-8 release in human primary epidermal keratinocytes after 6 hrs by HTRF assay2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
AID1231851Selectivity index, CC50 for african green monkey Vero cells to EC50 for HIV2 ROD2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID1231850Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID1305723Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Jatrophane and ingenane-type diterpenoids from Euphorbia kansui inhibit the LPS-induced NO production in RAW 264.7 cells.
AID1406277Antiviral activity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells measured on day 3 post infection by Nano-Glo luciferase reporter gene assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui.
AID1543132Antiviral activity against HIV NL4-3 infected in human MT4 cells measured on day 3 post-infection by Nano-Glo luciferase assay2019Journal of natural products, 06-28, Volume: 82, Issue:6
Potent Anti-HIV Ingenane Diterpenoids from Euphorbia ebracteolata.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (89)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (8.99)18.7374
1990's8 (8.99)18.2507
2000's20 (22.47)29.6817
2010's45 (50.56)24.3611
2020's8 (8.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.07 (24.57)
Research Supply Index4.56 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index77.55 (26.88)
Search Engine Supply Index2.11 (0.95)

This Compound (48.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (5.56%)5.53%
Reviews3 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other82 (91.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]